Of interest, a recently published Phase II clinical study of PARP inhibition using olaparib as monotherapy reported a clinical benefit in three of five patients with IDH-mutant chondrosarcoma (one patient with a partial response and two with stable disease persisting for more than 7 months) [17]. Here, IDH2 is linked to chondrosarcoma.